NCT04144023 2026-03-05
A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
Mayo Clinic
Phase 1 Recruiting
Clinical Trials
1 trialsCarcinoma, Intraductal, Noninfiltrating × Granulocyte-Macrophage Colony-Stimulating Factor × 90 days × Clear all